Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There is an increasing body of genetic and biochemical evidence that points toward lysosomal dysfunction as a risk factor for developing age-related neurodegenerative disorders, including Parkinson’s disease (PD).

The highest genetic risk factor for developing PD is loss-of-function mutations in the GBA gene, which encodes the lysosomal hydrolase acid beta-glucocerebrosidase, the enzyme deficient in the lysosomal storage disorder, Gaucher Disease. The exact mechanism(s) leading to increased risk of PD in Gaucher patients and GBA1 mutation carriers is unclear; however a generally well accepted concept in the PD community is that a critical relationship exists between endosomal-lysosomal dysfunction, an imbalance in glycosphingolipids (GSL), and the development of PD.

Developing therapies for the treatment of rare lysosomal storage disorders (LSD) and neurologic diseases is currently aligned with the overall strategic mission of the Rare Disease Research Unit (RDRU) at Pfizer.

Working with the Medical Sciences Business Partnerships team, Professor Fran Platt was able to secure funding for two years in the first instance to better understand endosomal-lysosomal dysfunction and the role of GSL in PD, potentially leading to identification of novel therapeutic targets for the treatment of this devastating disease.

Fran commented, "We are delighted to have this opportunity to work in partnership with Pfizer on the validation of a potential new therapeutic target for PD that we recently identified”.

Work on this project started in July, with the return of Fran’s lab to the Department of Pharmacology.

Similar stories

Fran Platt awarded 2023 Thudichum Medal

Pharmacology Head of Department, Professor Fran Platt, has been announced as the winner of the 2023 Thudichum Medal, presented by the Biochemical Society.

Join Pharmacology as the next Blaschko Fellow

Two year fellowship, offered in association with Linacre College, which offers full salary support, funding for travel and consumables and college accommodation. Join one of the existing groups in Pharmacology and develop your own research programme.

Sir Jon Symonds joins Pharmacology as a Visiting Fellow

The Department of Pharmacology is delighted to announce the appointment of Sir Jonathan Symonds CBE, Chair of the Board of GlaxoSmithKline, as a Visiting Fellow. Jon has been Chairman of the Board at GSK since September 2019.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.